| P2093 | author name string | George Talbot | |
| | Brad Spellberg | |
| | American Thoracic Society (ATS) | |
| | Infectious Diseases Society of America (IDSA) | |
| | American College of Chest Physicians (ACCP) | |
| | Society of Critical Care Medicine (SCCM) | |
| P2860 | cites work | Resistance in Nonfermenting Gram-Negative Bacteria: Multidrug Resistance to the Maximum | Q21710731 |
| | Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia | Q22241905 |
| | Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE | Q28276828 |
| | Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia | Q28286874 |
| | Inadequate treatment of ventilator-associated pneumonia: risk factors and impact on outcomes | Q79917087 |
| | Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study | Q80387733 |
| | Antimicrobial agents for complicated skin and skin-structure infections: justification of noninferiority margins in the absence of placebo-controlled trials | Q28393128 |
| | Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America | Q29616084 |
| | The "zero risk" concept for hospital-acquired infections: a risky business! | Q30379162 |
| | Considerations unique to pediatrics for clinical trial design in hospital-acquired pneumonia and ventilator-associated pneumonia | Q33624059 |
| | Position paper: recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia | Q33684318 |
| | Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription | Q33912931 |
| | Blinded invasive diagnostic procedures in ventilator-associated pneumonia | Q33921198 |
| | Recommendations for treatment of hospital-acquired and ventilator-associated pneumonia: review of recent international guidelines | Q34123866 |
| | Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options | Q36268383 |
| | The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species | Q36559359 |
| | Parenteral and inhaled colistin for treatment of ventilator-associated pneumonia | Q36559388 |
| | The clinical pulmonary infection score poorly predicts pneumonia in patients with burns | Q36702692 |
| | Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era? | Q36738598 |
| | Does this patient have ventilator-associated pneumonia? | Q36787675 |
| | Acinetobacter infection | Q37114411 |
| | Issues in noninferiority trials: the evidence in community-acquired pneumonia | Q37170063 |
| | Health care-associated pneumonia: identification and initial management in the ED. | Q37207881 |
| | Executive summary: workshop on issues in the design and conduct of clinical trials of antibacterial drugs in the treatment of community-acquired pneumonia | Q37217221 |
| | Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization | Q37302581 |
| | Historical and regulatory perspectives on the treatment effect of antibacterial drugs for community-acquired pneumonia | Q37318215 |
| | Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap! | Q37769530 |
| | End points in hospital-acquired pneumonia and/or ventilator-associated pneumonia clinical trials: food and drug administration perspective | Q37769532 |
| | Hospital-acquired pneumonia, health care-associated pneumonia, ventilator-associated pneumonia, and ventilator-associated tracheobronchitis: definitions and challenges in trial design | Q37769534 |
| | Surrogate markers and microbiologic end points | Q37769536 |
| | Ventilator-associated pneumonia: the clinical pulmonary infection score as a surrogate for diagnostics and outcome | Q37769537 |
| | Considerations in undertaking a clinical development program for hospital-acquired bacterial pneumonia and/or ventilator-associated bacterial pneumonia | Q37769538 |
| | Registration trials of antibacterial drugs for the treatment of nosocomial pneumonia | Q37769540 |
| | Challenges in the design and conduct of clinical trials for hospital-acquired pneumonia and ventilator-associated pneumonia: an industry perspective | Q37769541 |
| | Treatment guidelines and outcomes of hospital-acquired and ventilator-associated pneumonia | Q37769543 |
| | Other therapeutic modalities and practices: implications for clinical trials of hospital-acquired or ventilator-associated pneumonia | Q37769544 |
| | Ventilator-associated tracheobronchitis and pneumonia: thinking outside the box. | Q37769545 |
| | Use of severity scoring and stratification factors in clinical trials of hospital-acquired and ventilator-associated pneumonia | Q37769546 |
| | Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia | Q37769547 |
| | Diagnostic techniques and procedures for establishing the microbial etiology of ventilator-associated pneumonia for clinical trials: the pros for quantitative cultures | Q37769548 |
| | The argument against using quantitative cultures in clinical trials and for the management of ventilator-associated pneumonia | Q37769549 |
| | Pseudomonas aeruginosa susceptible only to colistin in intensive care unit patients | Q39211340 |
| | Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia | Q39608037 |
| | Impact of adequacy of initial antimicrobial therapy on the prognosis of patients with ventilator-associated pneumonia | Q39661220 |
| | Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria | Q39855993 |
| | Microscopic and bacteriological comparison of paired sputa and transtracheal aspirates | Q40237036 |
| | Correlates of clinical failure in ventilator-associated pneumonia: insights from a large, randomized trial | Q40423921 |
| | Bacterial sputum cultures. A clinician's viewpoint | Q40870667 |
| | Infections with Acinetobacter calcoaceticus (Herellea vaginicola): clinical and laboratory studies | Q40892705 |
| | The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America | Q41445493 |
| | High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. | Q42165253 |
| | Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome | Q43521705 |
| | A step closer to extreme drug resistance (XDR) in gram-negative bacilli | Q43876962 |
| | Combined endpoints: can we use them? | Q44153771 |
| | Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic "blind" bronchoalveolar lavage fluid | Q44492283 |
| | Predictive value of broncho-alveolar lavage fluid Gram's stain in the diagnosis of ventilator-associated pneumonia: a prospective study | Q44590378 |
| | Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System | Q44727502 |
| | The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee | Q45265404 |
| | Late onset ventilator-associated pneumonia due to multidrug-resistant Acinetobacter spp.: experience with tigecycline | Q46083242 |
| | Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study | Q46571062 |
| | Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia | Q46620650 |
| | Trends in antimicrobial resistance in health care-associated pathogens and effect on treatment | Q46851716 |
| | Appropriateness and delay to initiate therapy in ventilator-associated pneumonia | Q46875327 |
| | Efficacy of adequate early antibiotic therapy in ventilator-associated pneumonia: influence of disease severity. | Q47968515 |
| | Imipenem resistance among pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. | Q50788076 |
| | Microbiology of ventilator-associated pneumonia compared with that of hospital-acquired pneumonia. | Q50981341 |
| | The futility of the clinical pulmonary infection score in trauma patients. | Q51249149 |
| | Ventilator-associated pneumonia: breaking the vicious circle of antibiotic overuse. | Q51715668 |
| | Nosocomial pneumonia. A multivariate analysis of risk and prognosis. | Q52573110 |
| | Pneumonia in an intensive care unit. A 30-month experience. | Q53699257 |
| | Noninvasive versus invasive microbial investigation in ventilator-associated pneumonia: evaluation of outcome. | Q53908059 |
| | Ventilator-Associated Pneumonia | Q57237894 |
| | Intravenous Colistin as Therapy for Nosocomial Infections Caused by Multidrug‐Resistant Pseudomonas aeruginosa and Acinetobacter baumannii | Q63197407 |
| | Nosocomial infections in elderly patients in the United States, 1986-1990. National Nosocomial Infections Surveillance System | Q64128276 |
| | Microscopic and baceriologic analysis of expectorated sputum | Q66924649 |
| | Detection of nosocomial lung infection in ventilated patients. Use of a protected specimen brush and quantitative culture techniques in 147 patients | Q70414345 |
| | Diagnosis and treatment of ventilator-associated pneumonia--impact on survival. A decision analysis | Q71692585 |
| | The safety and diagnostic accuracy of minibronchoalveolar lavage in patients with suspected ventilator-associated pneumonia | Q72157684 |
| | Diagnostic accuracy of protected catheter sampling in ventilator-associated bacterial pneumonia | Q73386574 |
| | Clinical criteria in the diagnosis of ventilator-associated pneumonia | Q73803755 |
| | Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia | Q73984729 |
| | Impact of invasive and noninvasive quantitative culture sampling on outcome of ventilator-associated pneumonia: a pilot study | Q74225356 |
| | The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia | Q74304398 |
| | The long range effect of antibacterial therapy on pneumonia, empyema, bronchiectasis and pulmonary abscess; an analysis of incidence and mortality in 74,489 admissions to a Children's Hospital in twenty years | Q75940703 |
| | Hospital-acquired pneumonia: epidemiology, etiology, and treatment | Q77434764 |
| | A randomized trial of diagnostic techniques for ventilator-associated pneumonia | Q79445509 |
| | Diagnosis of ventilator-associated pneumonia | Q79445517 |
| | The changing global epidemiology of Acinetobacter baumannii infections: a development with major public health implications | Q79845986 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ventilator | Q813243 |
| | pneumonia | Q12192 |
| | bacterial pneumonia | Q3776920 |
| P304 | page(s) | S150-70 | |
| P577 | publication date | 2010-08-01 | |
| P1433 | published in | Clinical Infectious Diseases | Q5133764 |
| P1476 | title | Recommended design features of future clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia | |
| P478 | volume | 51 Suppl 1 | |